So far, research has shown that COVID-19 patients with NAFLD have a distinct cytokine profile including increased levels of IL-6, IL-8, IL-10, and CXCL10, all associated with a more severe clinical presentation [12,14,15,16,17]. Here, CXCL10 is linked to metabolic dysfunction-associated steatotic liver disease.